-
Simtuzumab (INN;
formerly GS 6624) is a
humanized monoclonal antibody designed for the
treatment of fibrosis. It
binds to LOXL2 and acts as an immunomodulator...
- dermatomyositis,
polymyositis Siltuximab Sylvant mab
chimeric IL-6 Y
cancer Simtuzumab mab
humanized LOXL2
fibrosis Sipavibart Kavigale mab
human spike protein...
-
several novel therapies,
including obeticholic acid (a bile acid analogue),
simtuzumab (a
monoclonal antibody), and 24-norursodeoxycholic acid (a
synthetic bile...
-
Phase II
clinical trials for IPF,
including the
monoclonal antibodies simtuzumab, tralokinumab,
lebrikizumab and FG-3019, a
lysophosphatidic acid receptor...
-
investigated as a
possible treatment for PSC due to its
antifibrotic effects.
Simtuzumab is a
monoclonal antibody against the
profibrotic enzyme LOXL2 that is...
-
cells to metastasize. An
antibody that
inhibits the
activity of LOXL2,
simtuzumab, is
currently in
clinical trials for the
treatment of
several types of...
-
Rosmantuzumab Rovalpituzumab tesirine†
Sacituzumab govitecan Sibrotuzumab§
Simtuzumab§
Sofituzumab vedotin§
Tacatuzumab tetraxetan§ Tigatuzumab§ Trastuzumab#...
-
Rosmantuzumab Rovalpituzumab tesirine†
Sacituzumab govitecan Sibrotuzumab§
Simtuzumab§
Sofituzumab vedotin§
Tacatuzumab tetraxetan§ Tigatuzumab§ Trastuzumab#...
-
Rosmantuzumab Rovalpituzumab tesirine†
Sacituzumab govitecan Sibrotuzumab§
Simtuzumab§
Sofituzumab vedotin§
Tacatuzumab tetraxetan§ Tigatuzumab§ Trastuzumab#...
